Abstract
Insight into the mechanisms of primary or acquired drug resistance of (hematological) malignancies is critical for the development of new treatment strategies. This review will focus on Bcl-2 and the mevalonate pathway as targets for reversal of drug resistance in multiple myeloma. The Bcl-2 protein is highly expressed in myeloma patients and in vitro studies have shown its role in the regulation of chemosensitivity, which makes Bcl-2 an attractive target for treatment. Statins are widely used for the treatment of hypercholesteremia. Several in vitro studies have shown that statins may also kill hematological malignant cells including myeloma cells. We found that lovastatin induced apoptosis in myeloma and lymphoma cells by inhibition of geranylgeranylation and subsequent down regulation of Mcl-1, probably the most important anti-apoptotic protein in myeloma. Phase 1 and 2 studies have been performed with Bcl-2 antisense oligonucleotides and high dose simvastatin in combination with chemotherapy in heavily pre-treated myeloma patients. Encouraging results from these studies may provide the framework for the future application of new treatment strategies for myeloma
Keywords: Multiple myeloma, drug resistance, apoptosis, proliferation, mevalonate pathway, geranylgeranylation, Bcl-2, Mcl-1
Current Pharmaceutical Design
Title: New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway
Volume: 12 Issue: 3
Author(s): Niels W.C.J. van de Donk, Andries C. Bloem, Ellen v. d. Spek and Henk M. Lokhorst
Affiliation:
Keywords: Multiple myeloma, drug resistance, apoptosis, proliferation, mevalonate pathway, geranylgeranylation, Bcl-2, Mcl-1
Abstract: Insight into the mechanisms of primary or acquired drug resistance of (hematological) malignancies is critical for the development of new treatment strategies. This review will focus on Bcl-2 and the mevalonate pathway as targets for reversal of drug resistance in multiple myeloma. The Bcl-2 protein is highly expressed in myeloma patients and in vitro studies have shown its role in the regulation of chemosensitivity, which makes Bcl-2 an attractive target for treatment. Statins are widely used for the treatment of hypercholesteremia. Several in vitro studies have shown that statins may also kill hematological malignant cells including myeloma cells. We found that lovastatin induced apoptosis in myeloma and lymphoma cells by inhibition of geranylgeranylation and subsequent down regulation of Mcl-1, probably the most important anti-apoptotic protein in myeloma. Phase 1 and 2 studies have been performed with Bcl-2 antisense oligonucleotides and high dose simvastatin in combination with chemotherapy in heavily pre-treated myeloma patients. Encouraging results from these studies may provide the framework for the future application of new treatment strategies for myeloma
Export Options
About this article
Cite this article as:
van de Donk W.C.J. Niels, Bloem C. Andries, Spek v. d. Ellen and Lokhorst M. Henk, New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway, Current Pharmaceutical Design 2006; 12 (3) . https://dx.doi.org/10.2174/138161206775201974
DOI https://dx.doi.org/10.2174/138161206775201974 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Stabilization of Eukaryotic Topoisomerase II-DNA Cleavage Complexes
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Embryonic Signaling Pathways as Potential Targets for the Treatment of Rhabdomyosarcoma)
Current Drug Targets Hepatoblastoma: Review of Pathology, Diagnosis and Modern Treatment Strategies
Current Cancer Therapy Reviews The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Current Pharmaceutical Design Anemia in Chronic Heart Failure - Clinical and Prognostic Significance
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Regulation of Ion Channels, Cellular Carriers and Na(+)/K(+)/ATPase by Janus Kinase 3
Current Medicinal Chemistry CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia
Cardiovascular & Hematological Disorders-Drug Targets Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?
Current Cancer Drug Targets Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Anticancer Drugs Targeting the Apoptotic Pathway
Medicinal Chemistry Reviews - Online (Discontinued) Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design Dual Receptor-Specific Peptides Modified Liposomes as VEGF siRNA Vector for Tumor-Targeting Therapy
Current Gene Therapy C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design Growth Factor Signaling and Resistance to Cancer Chemotherapy
Current Topics in Medicinal Chemistry Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry